Cargando…

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

AIMS: To evaluate dose levels for semaglutide, a glucagon‐like peptide‐1 analogue approved for the treatment of type 2 diabetes, by examining the effects of demographic factors on efficacy and safety in an exposure‐response analysis. METHODS: We analysed data from 1552 adults from four randomized ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petri, Kristin C. C., Ingwersen, Steen H., Flint, Anne, Zacho, Jeppe, Overgaard, Rune V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099226/ https://www.ncbi.nlm.nih.gov/pubmed/29748996 http://dx.doi.org/10.1111/dom.13358

Ejemplares similares

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
por: Overgaard, Rune V., et al.
Publicado: (2021)

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
por: Overgaard, Rune V., et al.
Publicado: (2021)

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
por: Ikushima, Ippei, et al.
Publicado: (2018)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Semaglutide for type 2 diabetes
Publicado: (2020)

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
por: Marbury, Thomas C., et al.
Publicado: (2017)

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
por: Kapitza, Christoph, et al.
Publicado: (2017)

Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach
por: Overgaard, Rune V., et al.
Publicado: (2018)

No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
por: Demmel, Valentin, et al.
Publicado: (2018)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
por: Røder, Michael E
Publicado: (2019)

Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development
por: Overgaard, RV, et al.
Publicado: (2015)

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
por: Kane, Michael P, et al.
Publicado: (2020)

Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
por: Reppo, Ingrid, et al.
Publicado: (2023)

Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study
por: Barrett, Annabel, et al.
Publicado: (2023)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
por: Iacobellis, Gianluca, et al.
Publicado: (2020)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
por: Gomez-Peralta, Fernando, et al.
Publicado: (2019)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson, Sam, et al.
Publicado: (2019)

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
por: Liu, Yalin, et al.
Publicado: (2022)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
por: Di Folco, Ugo, et al.
Publicado: (2022)

A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
por: Selvarajan, Raja, et al.
Publicado: (2023)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
por: Viljoen, Adie, et al.
Publicado: (2018)

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
por: Bain, Stephen C., et al.
Publicado: (2018)

Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing
por: Klonoff, David C, et al.
Publicado: (2020)

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
por: Marzullo, P., et al.
Publicado: (2022)

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
por: Hjerpsted, Julie B., et al.
Publicado: (2017)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
por: Newsome, Philip, et al.
Publicado: (2019)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3bf8peqpldp92bdc254kgheh11